Login to Your Account



The Xa Factor

Progress on Antidote for Next-Generation Anti-Clotting Drugs

By Anette Breindl
Science Editor

Wednesday, March 6, 2013
In the March 3, 2013, online edition of Nature Medicine, scientists from Portola Pharmaceuticals Inc. reported on its PRT064445, a recombinant and "ever so slightly engineered" version of Factor Xa that the company hopes will become a universal antidote to next-generation anti-clotting drugs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription